These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16103993)

  • 1. Synthetic RGD-containing alpha-helical coiled coil peptides promote integrin-dependent cell adhesion.
    Villard V; Kalyuzhniy O; Riccio O; Potekhin S; Melnik TN; Kajava AV; Rüegg C; Corradin G
    J Pept Sci; 2006 Mar; 12(3):206-12. PubMed ID: 16103993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells.
    Lanza P; Felding-Habermann B; Ruggeri ZM; Zanetti M; Billetta R
    Blood Cells Mol Dis; 1997 Aug; 23(2):230-41. PubMed ID: 9268674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibronectin modulates macrophage adhesion and FBGC formation: the role of RGD, PHSRN, and PRRARV domains.
    Kao WJ; Lee D; Schense JC; Hubbell JA
    J Biomed Mater Res; 2001 Apr; 55(1):79-88. PubMed ID: 11426401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
    Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
    J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
    Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
    Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New potent and selective αvβ
    Wu Z; Cheng X; Hong H; Zhao X; Zhou Z
    Bioorg Med Chem Lett; 2017 May; 27(9):1911-1913. PubMed ID: 28351594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic RGD and
    Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel dual-cyclic RGD peptides for α
    Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
    Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bicyclic RGD peptides with high integrin α
    Cipriani F; Bernhagen D; García-Arévalo C; de Torre IG; Timmerman P; Rodríguez-Cabello JC
    Biomed Mater; 2019 Mar; 14(3):035009. PubMed ID: 30630151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tetravalent RGD ligand for integrin-mediated cell adhesion.
    Watson N; Duncan G; Annan WS; van der Walle CF
    J Pharm Pharmacol; 2006 Jul; 58(7):959-66. PubMed ID: 16805956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
    Choi Y; Kim E; Lee Y; Han MH; Kang IC
    Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
    Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
    Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.
    Garanger E; Boturyn D; Coll JL; Favrot MC; Dumy P
    Org Biomol Chem; 2006 May; 4(10):1958-65. PubMed ID: 16688341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin.
    Richards J; Miller M; Abend J; Koide A; Koide S; Dewhurst S
    J Mol Biol; 2003 Mar; 326(5):1475-88. PubMed ID: 12595259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.
    Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A
    Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
    Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
    Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization.
    Wang W; Wu Q; Pasuelo M; McMurray JS; Li C
    Bioconjug Chem; 2005; 16(3):729-34. PubMed ID: 15898744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD and other recognition sequences for integrins.
    Ruoslahti E
    Annu Rev Cell Dev Biol; 1996; 12():697-715. PubMed ID: 8970741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family.
    Wu PL; Lee SC; Chuang CC; Mori S; Akakura N; Wu WG; Takada Y
    J Biol Chem; 2006 Mar; 281(12):7937-45. PubMed ID: 16407244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
    Dresner-Pollak R; Rosenblatt M
    J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.